{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:29:09Z","timestamp":1787639349237,"version":"build-2736575974"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2026-0344_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The global obesity pandemic is associated with a higher prevalence of youth-onset type 2 diabetes (T2D). Continuous glucose monitoring (CGM) is established in type 1 diabetes, however, evidence regarding its impact in pediatric T2D is limited. This study has analyzed (a)\u00a0clinical and metabolic characteristics in adolescents at T2D onset and (b)\u00a0the impact of CGM on glycemic control, patient satisfaction and disease management in youths with\u00a0T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0344_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      a) Clinical and biochemical parameters at diagnosis were assessed in adolescents with T2D. b) The impact of 8\u00a0weeks of CGM on HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , time in range (TIR), markers of the Metabolic Syndrome (MetS), lifestyle and treatment satisfaction were exploratively examined in a subgroup. HbA\n                      <jats:sub>1c<\/jats:sub>\n                      was subsequently monitored for 12\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0344_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Study a): Between 2018 and 2024, 24 adolescents were diagnosed with T2D (25\u202f% female; 14\u00a0\u00b1\u00a03 years; HbA\n                      <jats:sub>1c<\/jats:sub>\n                      : 9.9\u00a0\u00b1\u00a02.9\u202f%). Symptoms included polydipsia (45.8\u202f%), polyuria (33.3\u202f%), features of the MetS (100\u202f%), ketoacidosis (16.7\u202f%). Study b): 11 patients participated in the CGM study (14\u00a0\u00b1\u00a03 years). After 8\u00a0weeks, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      significantly decreased from 6.9\u00a0\u00b1\u00a01.1 to 6.4\u00a0\u00b1\u00a00.7\u202f%, TIR increased from 78.5\u00a0\u00b1\u00a030.3\u202f% to 87.1\u00a0\u00b1\u00a017.6\u202f%. More frequent glucose monitoring was reported by 91\u202f%, more appropriate responses to glucose fluctuations by 82\u202f%, improved quality of life and dietary habits by 73\u202f%. Ninety one percent of participants preferred CGM over capillary testing. HbA\n                      <jats:sub>1c<\/jats:sub>\n                      remained stable at 6\u00a0months (6.4\u00a0\u00b1\u00a00.9\u202f%) but increased to 6.9\u00a0\u00b1\u00a01.8\u202f% at 12\u00a0months after discontinuation of\u00a0CGM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0344_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In youth-onset T2D, CGM may improve glycemic outcomes and disease management\/quality of life. Larger studies are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2026-0344","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:59:14Z","timestamp":1787637554000},"source":"Crossref","is-referenced-by-count":0,"title":["Youth with type 2-diabetes: clinical findings at onset and impact of continuous glucose monitoring (CGM) on glycemic control and disease management"],"prefix":"10.1515","author":[{"given":"Rosa","family":"Thielemann","sequence":"first","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Greifoner","sequence":"additional","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Dieke","sequence":"additional","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kuplin","sequence":"additional","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Placzek","sequence":"additional","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[{"name":"Institute for Medical Epidemiology, Biometry and Informatics, Martin-Luther-University Halle-Wittenberg , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Weihrauch-Bl\u00fcher","sequence":"additional","affiliation":[{"name":"Department for Operative and Conservative Adolescent and Pediatric Medicine, Clinic for Pediatrics 1 , University Medicine Halle , Halle (Saale) , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082505585669084_j_jpem-2026-0344_ref_001","doi-asserted-by":"crossref","unstructured":"Lynch, JL, Barrientos-P\u00e9rez, M, Hafez, M, Jalaludin, MY, Kovarenko, M, Rao, PV, et al.. Country-specific prevalence and incidence of youth-onset type 2 diabetes: a narrative literature review. Ann Nutr Metab 2020;76:289\u201396. https:\/\/doi.org\/10.1159\/000510499.","DOI":"10.1159\/000510499"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_002","doi-asserted-by":"crossref","unstructured":"Lara-Castor, L, O\u2019Hearn, M, Cudhea, F, Miller, V, Shi, P, Zhang, J, et al.. Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries. Nat Med 2025;31:552\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03345-4.","DOI":"10.1016\/j.cdnut.2024.103510"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_003","doi-asserted-by":"crossref","unstructured":"Imperatore, G, Boyle, JP, Thompson, TJ, Case, D, Dabelea, D, Hamman, RF, et al.. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20\u00a0years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012;35:2515\u201320. https:\/\/doi.org\/10.2337\/dc12-0669.","DOI":"10.2337\/dc12-0669"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_004","doi-asserted-by":"crossref","unstructured":"Wagenknecht, LE, Lawrence, JM, Isom, S, Jensen, ET, Dabelea, D, Liese, AD, et al.. Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based SEARCH for diabetes in youth study. Lancet Diabetes Endocrinol 2023;11:242\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(23)00025-6.","DOI":"10.1016\/S2213-8587(23)00025-6"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_005","doi-asserted-by":"crossref","unstructured":"Wiegand, S, Becker, M, Schmid, S, Weghuber, D, Weihrauch-Bl\u00fcher, S, Reinehr, T, et al.. Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German-speaking countries: analysis based on the diabetes prospective follow-up registry. Diabetes Obes Metabol 2024;26:5630\u20135. https:\/\/doi.org\/10.1111\/dom.15930.","DOI":"10.1111\/dom.15930"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_006","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S148\u201364. https:\/\/doi.org\/10.2337\/dc19-S013.","DOI":"10.2337\/dc19-S013"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_007","doi-asserted-by":"crossref","unstructured":"Loh, C, Weihe, P, Kuplin, N, Placzek, K, Weihrauch-Bl\u00fcher, S. Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic. Metabolism 2021;122:154842. https:\/\/doi.org\/10.1016\/j.metabol.2021.154842.","DOI":"10.1016\/j.metabol.2021.154842"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_008","doi-asserted-by":"crossref","unstructured":"Zeitler, P. Progress in understanding youth-onset type 2 diabetes in the United\u00a0States: recent lessons from clinical trials. World J Pediatr 2019;15:315\u201321. https:\/\/doi.org\/10.1007\/s12519-019-00247-1.","DOI":"10.1007\/s12519-019-00247-1"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_009","doi-asserted-by":"crossref","unstructured":"Patel, D, Shah, AS, Magella, B, Bahrainian, M, Brown, EA, Liu, TYA, et al.. High rate of complications in a real-world cohort of youth with T2D: a multicenter analysis. J\u00a0Diabet Complicat 2025;39:109091. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109091.","DOI":"10.1016\/j.jdiacomp.2025.109091"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_010","doi-asserted-by":"crossref","unstructured":"Bjornstad, P, Drews, KL, Caprio, S, Gubitosi-Klug, R, Nathan, DM, Tesfaldet, B, et al.. Long-term complications in youth-onset type 2 diabetes. N\u00a0Engl J Med 2021;385:416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2100165.","DOI":"10.1530\/ey.19.12.3"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_011","doi-asserted-by":"crossref","unstructured":"Weinstock, RS, Aleppo, G, Bailey, TS, Bergenstal, RM, Fisher, WA, Greenwood, DA, et al.. The role of blood glucose monitoring in diabetes management. ADA Clin Compend 2020;2020. https:\/\/doi.org\/10.2337\/db2020-31.","DOI":"10.2337\/db2020-31"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_012","doi-asserted-by":"crossref","unstructured":"Tan, YY, Suan, E, Koh, GCH, Suhairi, SB, Tyagi, S. Effectiveness of continuous glucose monitoring in patient management of type 2 diabetes mellitus: an umbrella review of systematic reviews from 2011 to 2024. Arch Public Health 2024;82:231. https:\/\/doi.org\/10.1186\/s13690-024-01459-2.","DOI":"10.1186\/s13690-024-01459-2"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_013","doi-asserted-by":"crossref","unstructured":"Elbalshy, M, Haszard, J, Smith, H, Kuroko, S, Galland, B, Oliver, N, et al.. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Diabet Med 2022;39:e14854. https:\/\/doi.org\/10.1111\/dme.14854.","DOI":"10.1111\/dme.14854"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_014","unstructured":"National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management; 2015. https:\/\/www.nice.org.uk\/guidance\/ng18 [Accessed 11 Mar 2025]."},{"key":"2026082505585669084_j_jpem-2026-0344_ref_015","unstructured":"Deutsche Diabetes Gesellschaft e.V. S3-Leitlinie Diagnostik. Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter; 2023. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/057-016 [Accessed 2 Apr 2025]."},{"key":"2026082505585669084_j_jpem-2026-0344_ref_016","doi-asserted-by":"crossref","unstructured":"Shah, AS, Zeitler, PS, Wong, J, Pena, AS, Wicklow, B, Arslanian, S, et al.. ISPAD Clinical Practice Consensus Guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes 2022;23:872\u2013902. https:\/\/doi.org\/10.1111\/pedi.13409.","DOI":"10.1111\/pedi.13409"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_017","unstructured":"Neuhauser, H, Schienkiewitz, A, Schaffrath Rosario, A, Dortschy, R, Kurth, B-M. Referenzperzentile f\u00fcr anthropometrische Ma\u00dfzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS), 2nd ed. Berlin: Robert Koch-Institut; 2013."},{"key":"2026082505585669084_j_jpem-2026-0344_ref_018","doi-asserted-by":"crossref","unstructured":"Kromeyer-Hauschild, K, Wabitsch, M, Kunze, D, Geller, F, Gei\u00df, HC, Hesse, V, et al.. Perzentile f\u00fcr den body-mass-index f\u00fcr das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001;149:807\u201318. https:\/\/doi.org\/10.1007\/s001120170107.","DOI":"10.1007\/s001120170107"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_019","doi-asserted-by":"crossref","unstructured":"Wolfsdorf, JI, Glaser, N, Agus, M, Fritsch, M, Hanas, R, Rewers, A, et al.. ISPAD Clinical Practice Consensus Guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 2018;19:155\u201377. https:\/\/doi.org\/10.1111\/pedi.12701.","DOI":"10.1111\/pedi.12701"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_020","doi-asserted-by":"crossref","unstructured":"Kromeyer-Hauschild, K, Neuhauser, H, Schaffrath Rosario, A, Schienkiewitz, A. Abdominal obesity in German adolescents defined by waist-to-height ratio and its association to elevated blood pressure: the KiGGS study. Obes Facts 2013;6:165\u201375. https:\/\/doi.org\/10.1159\/000351066.","DOI":"10.1159\/000351066"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_021","doi-asserted-by":"crossref","unstructured":"Zimmet, P, Alberti, KGM, Kaufman, F, Tajima, N, Silink, M, Arslanian, S, et al.. The metabolic syndrome in children and adolescents\u00a0\u2013\u00a0an IDF consensus report. Pediatr Diabetes 2007;8:299\u2013306. https:\/\/doi.org\/10.1111\/j.1399-5448.2007.00271.x.","DOI":"10.1111\/j.1399-5448.2007.00271.x"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_022","doi-asserted-by":"crossref","unstructured":"Patel, T, Sala, NGL, Macheret, NA, Glaros, SB, Dixon, SD, Meyers, A, et al.. Continuous glucose monitoring use in youth with type 2 diabetes: a pilot randomized study. Diabetes Technol Therapeut 2025;27:623\u201330. https:\/\/doi.org\/10.1089\/dia.2024.0539.","DOI":"10.1089\/dia.2024.0539"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_023","doi-asserted-by":"crossref","unstructured":"Chang, N, Barber, ROB, Llovido Alula, J, Durazo-Arvizu, R, Chao, LC. Continuous glucose monitoring versus standard of care in adolescents with type 2 diabetes: a pilot randomized cross-over trial. J\u00a0Diabetes Sci Technol 2023;17:1419\u201320. https:\/\/doi.org\/10.1177\/19322968231178284.","DOI":"10.1177\/19322968231178284"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_024","doi-asserted-by":"crossref","unstructured":"Chesser, H, Srinivasan, S, Puckett, C, Gitelman, SE, Wong, JC. Real-time continuous glucose monitoring in adolescents and young adults with type 2 diabetes can improve quality of life. J\u00a0Diabetes Sci Technol 2024;18:911\u20139. https:\/\/doi.org\/10.1177\/19322968221139873.","DOI":"10.1177\/19322968221139873"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_025","doi-asserted-by":"crossref","unstructured":"Manfredo, J, Lin, T, Gupta, R, Abiola, K, West, M, Busin, K, et al.. Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications. Front Endocrinol 2023;14:1182260. https:\/\/doi.org\/10.3389\/fendo.2023.1182260.","DOI":"10.3389\/fendo.2023.1182260"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_026","doi-asserted-by":"crossref","unstructured":"Serbis, A, Giapros, V, Kotanidou, EP, Galli-Tsinopoulou, A, Siomou, E. Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents. World J Diabetes 2021;12:344\u201365. https:\/\/doi.org\/10.4239\/wjd.v12.i4.344.","DOI":"10.4239\/wjd.v12.i4.344"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_027","doi-asserted-by":"crossref","unstructured":"Dabelea, D, Rewers, A, Stafford, JM, Standiford, DA, Lawrence, JM, Saydah, S, et al.. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 2014;133:e938\u201345. https:\/\/doi.org\/10.1542\/peds.2013-2795.","DOI":"10.1542\/peds.2013-2795"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_028","doi-asserted-by":"crossref","unstructured":"Cara, JF, Chaiken, RL. Type 2 diabetes and the metabolic syndrome in children and adolescents. Curr Diabetes Rep 2006;6:241\u201350. https:\/\/doi.org\/10.1007\/s11892-006-0041-8.","DOI":"10.1007\/s11892-006-0041-8"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_029","doi-asserted-by":"crossref","unstructured":"Lanzinger, S, Best, F, Bergmann, T, Laimer, M, Lipovsky, B, Danne, T, et al.. Dynamics of Hemoglobin A1c, body mass index, and rates of severe hypoglycemia in 4434 adults with type 1 or type 2 diabetes after initiation of continuous glucose monitoring. Diabetes Technol Therapeut 2022;24:763\u20139. https:\/\/doi.org\/10.1089\/dia.2022.0063.","DOI":"10.1089\/dia.2022.0063"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_030","doi-asserted-by":"crossref","unstructured":"Chen, Y-Y, Lin, Y-J, Chong, E, Chen, P-C, Chao, T-F, Chen, S-A, et al.. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. PLoS One 2015;10:e0123116. https:\/\/doi.org\/10.1371\/journal.pone.0123116.","DOI":"10.1371\/journal.pone.0123116"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_031","doi-asserted-by":"crossref","unstructured":"Aleppo, G, Beck, RW, Bailey, R, Ruedy, KJ, Calhoun, P, Peters, AL, et al.. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care 2021;44:2729\u201337. https:\/\/doi.org\/10.2337\/dc21-1304.","DOI":"10.2337\/dc21-1304"},{"key":"2026082505585669084_j_jpem-2026-0344_ref_032","unstructured":"Robert Koch-Institut. Diabetes typ 2: pr\u00e4valenz (11\u00a0\u2013\u00a017 Jahre). Gesundheitsberichterstattung des Bundes 2024. https:\/\/gbe.rki.de [Accessed 19 May 2026]."},{"key":"2026082505585669084_j_jpem-2026-0344_ref_033","doi-asserted-by":"crossref","unstructured":"Denzer, C, Prinz, N, Ovcarov, O, Fiedler, M, Amst\u00e4tter, T, Bauer, A, et al.. Typ-2-Diabetes bei Kindern und Jugendlichen\u00a0\u2013\u00a0Notwendigkeit eines innovativen Versorgungskonzepts. Monatsschr Kinderheilkd 2025. https:\/\/doi.org\/10.1007\/s00112-025-02284-9.","DOI":"10.1007\/s00112-025-02284-9"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0344\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:59:17Z","timestamp":1787637557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0344\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":33,"alternative-id":["10.1515\/jpem-2026-0344"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0344","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}